Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed...

Area of Science:

• Neuro-oncology
• Clinical oncology
• Radiochemotherapy

Background:

• Standard glioblastoma (GBM) treatment involves chemoradiotherapy with temozolomide (TMZ) post-surgery, yielding a median overall survival (OS) of 14.6 months.
• Investigating early TMZ chemotherapy between surgery and chemoradiotherapy aims to improve GBM patient outcomes.

Purpose of the Study:

• To evaluate the effectiveness and safety of incorporating early temozolomide (TMZ) chemotherapy between surgery and standard chemoradiotherapy for newly diagnosed glioblastoma (GBM) patients.

Main Methods:

• A randomized, open-label study involving 99 newly diagnosed GBM patients across 10 Chinese neurosurgical departments.
• Patients received either concomitant radiochemotherapy with early postsurgical TMZ or the standard concomitant radiochemotherapy regimen.
• Primary endpoint was overall survival (OS); secondary endpoint was progression-free survival (PFS).

Main Results:

• The early TMZ group showed a median OS of 17.6 months versus 13.2 months in the control group (P=0.021).
• OS rates at 6, 12, and 18 months were significantly higher in the early TMZ group.
• Median PFS was 8.7 months for early TMZ and 10.4 months for the control group (P=0.695); adverse events were comparable and generally mild.

Conclusions:

• Early TMZ chemotherapy, integrated into the treatment gap, is well-tolerated and significantly enhances OS in GBM patients compared to standard care.
• Further validation through larger randomized trials is recommended to confirm these findings.